CN Bio Innovations
CN Bio Innovations develops human organ-on-a-chip technologies: devices that enable the formation of miniature models of organs in the lab using living human cells.
Animal testing has traditionally been an important way scientists can find out if drugs are likely to be safe and effective, but CN Bio’s organ-on-a-chip devices now provide a viable and more precise way to predict patient responses to new medicines.
Over the past 3 years more than 25 pharmaceutical companies have used CN Bio’s devices to study the effects of drugs and other chemicals on organ function. CN Bio is also developing organ-on-chip models for specific diseases including non-alcoholic steatohepatitis and Hepatitis B. CN Bio is a co-recipient with MIT of a $26M US Federal contract to develop a human body-on-a-chip incorporating 10 interconnected mini organs and has also received grant awards from Innovate UK. In 2016 CN Bio successfully showcased the world’s first 7-organ-on-a-chip platform.
In joining the Alliance for Human Relevant Science, CN Bio will support a coalition of organisations which are committed to non-animal technologies. A significant part of this initiative is to work to improve the evidence base for non-animal technologies, providing viable alternative approaches to animal testing for both basic research and drug discovery. By working with regulators, funding bodies and industry to provide the evidence they need to support alternative technologies we hope to achieve a beneficial reduction in animal testing.